Basel, Switzerland, Oct. 16, 2017-Clinerion announces that data integration to its Patient Recruitment System platform can now also process electronic medical records made available by hospitals using the (FHIR) standard. Hospitals using FHIR may now directly exchange data with Patient Recruitment System without the need for additional implementation effort. Fast Healthcare Interoperability Resources (FHIR) is a data exchange standard released by the Health Level Seven International (HL7) health-care standards organization for exchanging healthcare information electronically. FHIR is the latest connector technology which can be accommodated by Clinerion’s Patient Recruitment System. Clinerion’s highly flexible data integration system can handle different data models and standards. This covers i2b2 and more than ten other models used in different hospital information systems worldwide. In addition to FHIR, data exchange with Patient Recruitment System is also possible with the standards HL7, OMOP, and RIM (the last two also released by HL7). Clinerion’s Patient Recruitment System processes electronic patient data at its network of partner hospitals for the provision of its services for clinical trial patient search and identification, data generation for real-world evidence, and market access activities. The patient data are fully anonymized, but Clinerion’s “Anonymized Identification” technology allows authorized hospital staff to re-identify patients on-site for clinical trials. Connection with Patient Recruitment System involves ETL (“exchange, transform, load”) push of anonymized patient data from the hospital’s internal hospital information system to a Patient Recruitment System server installed inside the hospital’s secure IT infrastructure. Patient data security is maintained because the ETL push is fully under the control of the hospital’s IT staff and all patient data stays within the local network of the hospitals. “Patient Recruitment System has always been interoperable with every available electronic health records system currently used-it has been an essential part of our offering,” says Andreas Walter, Clinerion Chief Technology Officer. “The introduction of the FHIR standard to the Clinerion offering simply means we now have standardized processes in place to accommodate FHIR and can therefore react much more quickly than before. With this, we are not only adding additional data input possibilities for standard data models, but also the ability to connect to a large set of HIS systems.” About Clinerion Clinerion enables early patient access to innovative treatments through solutions for clinical trial patient recruitment, real-world evidence, and market access. Clinerion's Patient Recruitment System accelerates clinical research by radically improving the efficiency and effectiveness of trial recruitment. Clinerion’s key patient data services include data-assisted protocol optimization, site feasibility evaluation and patient identification. Clinerion’s solutions allow member hospitals to participate in leading-edge, industry-sponsored trials and save time in patient recruitment. They enable pharmaceutical companies to gain time and save costs by streamlining operations and leveraging strategic intelligence. Clinerion’s proprietary Big Data analytics technologies leverage real-time data from electronic health records which remain under the full control of participating hospitals. Clinerion is a global data technology company headquartered in Switzerland. Clinerion's solutions follow international patient privacy and data security standards. Clinerion website: www.clinerion.com Clinerion’s Patient Recruitment System: www.clinerion.com/index/OverviewOurSolutions/PatientRecruitmentSystem For more information, please contact: Le Vin Chin Head of Marketing and Communications Clinerion Ltd Margarethenstrasse 47, CH-4053 Basel, Switzerland Tel.: +41 61 865 60 54 media@clinerion.com
Using Patient Reported Outcomes in Dermatology Trials
April 25th 2024In part 3 of this video interview with ACT editor Andy Studna, Melissa Mooney, director, eCOA sales engineering, IQVIA sheds light on the unique challenges of dermatology trials and how clinical outcome assessments can be implemented in them.
Including Women of Childbearing Age in Clinical Research
March 26th 2024In recognition of International Women's Month, we're featuring this recent talk between Associate Editor Miranda Schmalfuhs and Marie Teil, Global Head of UCB’s Women of Childbearing Age Program. They speak about the specific challenges women with chronic illnesses face when accessing appropriate treatment and participating in clinical trials, UCB's Women of Childbearing Age Program and it’s most successful strategies, and much more.
Improving Engagement While Maintaining Data Integrity & Validity
March 19th 2024In recognition of Women's Health Month, we're featuring this recent talk between Associate Editor Miranda Schmalfuhs and uMotif's Chief Product Officer, Julia Lakeland, discuss new technologies improving patient engagement and reducing the emotional and logistical burdens of participation, ethical considerations that should be addressed when implementing those technologies, while ensuring patient privacy, and much more.
FDA Grants Ziftomenib with Breakthrough Therapy Designation for NPM1-Mutant Acute Myeloid Leukemia
April 23rd 2024Data from the Phase Ib portion of the KOMET-001 trial showed that the once-daily oral treatment may provide a substantial improvement over available therapies for relapsed/refractory NPM1-mutant acute myeloid leukemia.